Online inquiry

IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3052MR)

This product GTTS-WQ3052MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets PTK7 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001270398.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5754
UniProt ID Q13308
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ3052MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6076MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CNTO 888
GTTS-WQ12084MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MOR-03087
GTTS-WQ6417MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CT-011
GTTS-WQ8995MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMA-638
GTTS-WQ2791MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG-282
GTTS-WQ7726MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GLP-1Fc
GTTS-WQ3305MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ASN-100
GTTS-WQ11688MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MHAB5553A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW